<DOC>
	<DOCNO>NCT01283984</DOCNO>
	<brief_summary>AZD2115 Single Ascending Dose Study</brief_summary>
	<brief_title>AZD2115 Single Ascending Dose Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy male subject age 18 45 year suitable vein cannulation repeat venepuncture Male subject willing use barrier contraception ie , condom spermicide , day dose 3 month dose investigational product . Have body mass index ( BMI ) 18 30 kg/m2 weigh least 50 kg 100 kg Be able inhale Spira nebuliser accord give instruction Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome Any clinically important abnormality heart rhythm , conduction morphology rest ECG may interfere interpretation QTc interval change . This include subject follow : PR ( PQ ) interval prolongation &gt; 200 m ( first degree AV block ) Intermittent second third degree AV block ( base screen predose ECG ) Incomplete , full intermittent bundle branch block ( QRS &lt; 110 m normal QRS T wave morphology acceptable evidence leave ventricular hypertrophy ) Abnormal T wave morphology , particularly protocol define primary lead Dropped beat History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD2115 and/or excipients History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug Serum potassium concentration &lt; 3.80 mmol/L admission ( Day 1 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>healthy</keyword>
	<keyword>inhale</keyword>
	<keyword>respiratory disease</keyword>
</DOC>